ZHAO

赵春顺

教授

研究领域：智能药物递送

办公电话： 020-39943118

联系邮箱： zhaocs@mail.sysu.edu.cn

赵春顺   博士，教授，博士生导师。2003年毕业于沈阳药科大学药剂学专业，获理学博士学位；1995-1997年于河北制药集团从事新药研发工作；1999-2000年于石药集团从事新药研发工作；2009-2010年在北卡罗来纳大学教堂山分校药学院从事靶向递药系统研究；2003年入职中山大学药学院。近几年负责国家科技重大专项“新药研究开发关键技术研究”专项、“大品种技术改造”专项、国家自然科学基金、广东省科技计划重点项目、平台项目、广州市科技计划重大项目等多项课题。同时，负责并完成企业合作项目30余项；申请专利9项，授权7项；国际PCT 2项，目前已获15个国家授权；发表研究论文60余篇。

研究方向

智能药物递送

教学情况

本科生：药剂学；药物制剂设计策略与实例

研究生：药物吸收与剂型设计

主持科研项目

  1. 国家自然科学基金面上项目，“基于II型幽门螺旋杆菌为载体的胃癌光动力-免疫治疗及免疫微环境重塑” （2022-2025）
  2. 国家自然科学基金面上项目，“原位肿瘤疫苗的光激活协同IDO阻断和抗骨重吸收用于乳腺癌骨转移治疗的研究” （2020-2023）
  3. 国家自然科学基金面上项目，“基于光触发同步释放ROS与药物的眼内长效植入系统的构建及其用于后囊浑浊防治的评价” （2017-2020）
  4. 国家自然科学基金面上项目，“双功能晶状体囊袋植入系统的构建与性能评价” （2012-2015）
  5. 广东省科技计划重点项目，“抗缺血性脑卒中候选药物--异吲哚酮类化合物的筛选及临床前研究”，（2015B020211005）
  6. 国家科技重大专项“重大新药创制”项目“新药研究开发关键技术研究”专项，“高生物利用度及稳定性药物晶型的制备与分析技术及产业化应用”,（2009ZX09501-022，分题负责人）；
  7. 国家科技重大专项“重大新药创制”项目“大品种技术改造”专项，“丁苯酞高端制剂及其作用靶点、机理研究”，（2008ZX09201-007，分题负责人）；

研究论文

  1. ZQ Huang#, Y Luo#, T Zhang#, YQ Ding, MX Chen, J Chen, QX Liu, YJ Huang, and CS Zhao*. A Stimuli-Responsive Small-Molecule Metal-Carrying Prochelator: A Novel Prodrug Design Strategy for Metal Complexes. Angew Chem Int Ed. 2022; 61(28):e202203500. 
  2. J Chen#, XM Tan#, YJ Huang#*, CJ Xu, ZS Zeng, T Shan, ZL Guan, XY Xu, ZQ Huang, CS Zhao*. Reactive oxygen species-activated self-amplifying prodrug nanoagent for tumor-specific Cu-chelate chemotherapy and cascaded photodynamic therapy. Biomaterials. 2022; 284:121513. 
  3. MX Chen, ZQ Huang, M Xia, YQ Ding, T Shan, ZL Guan, XL Dai, XY Xu, YJ Huang, M Huang, CS Zhao*. Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy. J. Control Release. 2022; 341:351-363. 
  4. Y Luo#, ZS Zeng#, T Shan, XY Xu, J Chen, YF He, T Zhang, ZQ Huang, GH Chai, YJ Huang, YF Zhao, and CS Zhao*. Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy. Theranostics. 2022 May 1;12(8):3610-3627.
  5. ZQ Huang#, YQ Ding#, Y Luo, MX Chen, ZS Zeng, T Zhang, Yue Sun, YJ Huang, CS Zhao*. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy. Acta Biomaterialia. 2022; 152:367–379.
  6. YJ Huang#, XL Dai#, ZL Guan#, Di Liu, LL Ren, MX Chen, ZS Zeng, Jingwen Jiang, Y Luo, YF He, M Huang, CS Zhao*. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking. Int J Pharm. 2022; 622:121897. 
  7. XY Xu, ZS Zeng, X Ding, T Shan, QX Liu, MX Chen, J Chen, M Xia, YF He, ZQ Huang, YJ Huang, CS Zhao*. Reactive oxygen species-activatable self-amplifying Watson-Crick base pairing-inspired supramolecular nanoprodrug for tumor-specific therapy. Biomaterials, 2021; 227:121128. 
  8. CJ Xu,† ZH Xiao,† J Wang, HL Lai, T Zhang, ZL Guan, M Xia, MX Chen, LL Ren, YF He, Y Gao, and CS Zhao*. Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer. J Med Chem. 2021, 64(18):13312-13326. 
  9. YF Shen, CJ Xu, J Chen, ZL Guan, YJ Huang, ZS Zeng, XY Xu, XM Tan, CS Zhao*. Phototriggered Self-Adaptive Functionalized MOC-Based Drug Delivery Platform Promises High Antitumor Efficacy. Adv Healthc Mater. 2021, 10(19):e2100676. 
  10. CJ Xu, HL Yang, ZH Xiao, T Zhang, ZL Guan, J Chen, HL Lai, XY Xu, YJ Huang, ZQ Huang, CS Zhao*. Reduction-responsive dehydroepiandrosterone prodrug nanoparticles loaded with camptothecin for cancer therapy by enhancing oxidation therapy and cell replication inhibition. Int J Pharm. 2021; 603:120671. 
  11. ZQ Huang, YJ Huang, MX Chen, J Chen, ZS Zeng, XY Xu, BY Huang, Y Luo, ZH Xiao, YQ Ding, CS Zhao*. Bone-targeted oxidative stress nanoamplifier for synergetic chemo/chemodynamic therapy of bone metastases through increasing generation and reducing elimination of ROS. Chem. Eng. J., 2020; 399:125667.
  12. XY Xu, ZS Zeng, J Chen, BY Huang, ZL Guan, YJ Huang, ZQ Huang, CS Zhao*. Tumor-targeted supramolecular catalytic nanoreactor for synergistic chemo/chemodynamic therapy via oxidative stress amplification and cascaded Fenton reaction. Chem. Eng. J., 2020; 390:124628.
  13. YJ Huang#, YL Jiang#, ZH Xiao#, YF Shen, LF Huang, XY Xu, GF Wei, CJ Xu, CS Zhao⁎ . Three birds with one stone: A ferric pyrophosphate based nanoagent for synergetic NIR-triggered photo/ chemodynamic therapy with glutathione depletion. Chem. Eng. J., 2020;380:122369.
  14. XY Xu#, BY Huang#, ZS Zeng, J Chen, ZQ Huang, ZL Guan, MX Chen, YJ Huang, CS Zhao*. Broaden sources and reduce expenditure: Tumor-specific transformable oxidative stress nanoamplifier enabling economized photodynamic therapy for reinforced oxidation therapy. Theranostics, 2020; 10(23): 10513-10530. 
  15. XY Xu, ZS Zeng, ZQ Huang, YW Sun, YJ Huang, J Chen, JX Ye, HL Yang, CZ Yang, CS Zhao⁎. Near-infrared light-triggered degradable hyaluronic acid hydrogel for ondemand drug release and combined chemo-photodynamic therapy. Carbohyd Polym, 2020; 229:115394.
  16. XQ Sun, Di Liu, XY Xu, YF Shen, YJ Huang, ZS Zeng, M Xia, CS Zhao*. NIR-triggered thermo-responsive biodegradable hydrogel with combination of photothermal and thermodynamic therapy for hypoxic tumor. Asian J Pharm Sci, 2020; 15(6): 713-727.
  17. ZQ Huang#, GF Wei#, ZS Zeng, YJ Huang, LF Huang, YF Shen, XQ Sun, CJ Xu, CS Zhao*. Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. Theranostics, 2019; 9(19):5542-5557.
  18. LF Huang#, GF Wei#,*, XQ Sun, YL Jiang, ZQ Huang, YJ Huang, YF Shen, XY Xu, YH Liao, CS Zhao*. A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy. Eur J Med Chem., 2018; 151: 294-303.
  19. XF Zhang, BY Huang, YF Shen, CZ Yang, ZQ Huang, YJ Huang, XY Xu, YL Jiang, XQ Sun, XN Li, MN Yan and CS Zhao*. Near infrared light triggered reactive oxygen species responsive nanoparticles for chemo-photodynamic combined therapy. J. Mater. Chem. B, 2018; 6: 2347-2357.
  20. XY Xu, ZY Huang, ZQ Huang, XF Zhang, SY He, XQ Sun, YF Shen, MN Yan, CS Zhao*. Injectable, NIR/pH-Responsive Nanocomposite Hydrogel as Long-Acting Implant for Chemo-Photothermal Synergistic Cancer Therapy. ACS Appl Mater Interfaces. 2017;9(24):20361-20375
  21. WJ Chu, YJ Huang, CZ Yang, YH Liao, XF Zhang, MN Yan, SM Cui*, CS Zhao*. Calcium phosphate nanoparticles functionalized with alendronate- conjugated polyethylene glycol (PEG) for the treatment of bone metastasis. Int J Pharm., 2017; 516(1-2):352–363
  22. MN Yan, CZ Yang, BY Huang, ZQ Huang, LF Huang, XF Zhang, CS Zhao*. Systemic toxicity induced by aggregated layered double hydroxide nanoparticles.  Int J Nanomed., 2017; 12: 7183–7195.
  23. JN Huang, WY Gong, ZQ Chen, JY Huang, QH Chen, HQ Huang*, CS Zhao*. Emodin self-emulsifying platform ameliorates the expression of FN, ICAM-1 and TGF-β1 in AGEs-induced glomerular mesangial cells by promoting absorption. Eur J Pharm Sci., 2017; 99:128-136.
  24. M Lei, ZH Peng, Q Dong, YF He, ZG Zhang, XF Zhang, MN Yan, CS Zhao*. A Novel Capsular Tension Ring as Local Sustained-Release Carrier for Preventing Posterior Capsule Opacification. Biomaterials, 2016; 89:148-156.
  25. YH Liao, XF Zhang, CL Li, YJ Huang, M Lei, MN Yan, YF Zhou, CS Zhao*. Inclusion complexes of HP-β-cyclodextrin with agomelatine: Preparation, characterization, mechanism study and in vivo evaluation. Carbohyd Polym, 2016;147: 415–425
  26. ZG Zhang, WY Huang, M Lei, YF He, MN Yan, XF Zhang, CS Zhao*. Laser-triggered intraocular implant to induce photodynamic therapy for posterior capsule opacification prevention. Int J Pharm., 2016;498:1-11
  27. MN Yan, ZG Zhang, SM Cui, XF Zhang, WJ Chu, M Lei, Ke Zeng, YH Liao, YH Deng*, CS Zhao*. Preparation and evaluation of PEGylated phospholipid membrane coated layered double hydroxide nanoparticles. Asian J of Pharm. Sci., 2016:396-403
  28. ZJ Lan, XY Xu, WK Xu, J Li, ZR Liang, XF Zhang, M Lei, CS Zhao*. Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent. Drug Des Devel Ther., 2015;9:3377-3391
  29. MN Yan, ZG Zhang, SM Cui, M Lei, K Zeng, YH Liao, WJ Chu, YH Deng*, CS Zhao*. Improvement of pharmacokinetic and antitumor activity of layered double hydroxide nanoparticles by coating with PEGylated phospholipid membrane. Int J Nanomed., 2014;9(1):4867-4878
  30. YF Zhou, WJ Chu, M Lei, J Li, W Du, CS Zhao*. Application of a continuous intrinsic dissolution-permeation system for relative bioavailability estimation of polymorphic drugs. Int J Pharm., 2014;473(1-2):250-258.
  31. Q Dong, SL Yi, ZH Peng, CS Zhao*. The preparation and the in vitro pharmacodynamics study of the intracapsular prolong-preparations for the prevention of posterior capsule opacification. Asian J of Pharm. Sci., 2013;8(5):259-267
  32. W Du, YF Zhou, YF Gong, CS Zhao*. Investigation of physicochemical properties and in-vitro in-vivo evaluation of agomelatine polymorphs. Asian J of Pharm. Sci., 2013;8(4):181-190
  33. Y Xiao, HF Zhang, ZG Zhang, MN Yan, M Lei, Ke Zeng, CS Zhao*. Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on the hepatocyte targeting efficiency in vitro and in vivo. Int J Nanomed., 2013; 8:3033-3050.
  34. WW Li, SL Yi, ZH Wang, S Chen, S Xin, JW Xie, CS Zhao*. Self-nanoemulsifying drug delivery system of persimmon leaf extract: Optimization and bioavailability studies. Int J Pharm., 2011; 420(1):161-171.